Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Kendra L. Sweet, MD, Naveen Pemmaraju, MD, Andrew A Lane, MD PhD, Anthony S. Stein, MD, Sumithira Vasu, MBBS, William Blum, MD, David A. Rizzieri, MD, Eunice S. Wang, MD, Eric K. Rowinsky, MD, Michael Szarek, PhD, Christopher L. Brooks, PhD, Sarah Disalvatore, MPH, David Liu, Madeleine Duvic, MD, Jonathan D. Schwartz, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 3795.

https://doi.org/10.1182/blood.V126.23.3795.3795

Published: 2015

Journal Articles

Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission

Todd A. Fehniger, MD PhD, Robert K Stuart, MD, Sarah A. Cooley, MD MS, Jeffrey S. Miller, MD, Julie Curtsinger, PhD, Timothy Mark Hillman, MSc, Nova Silver, RN, Michael Szarek, PhD, Mark W Lowdell, BSc, MSc, PhD FRCPath, Leonid Gorelik, PhD, Eric Rowinsky, MD

Blood (2014) 124 (21): 2320.

https://doi.org/10.1182/blood.V124.21.2320.2320

Published: 2014

Journal Articles

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Arthur E. Frankel, Jung H. Woo, Chul Ahn, Naveen Pemmaraju, Bruno C. Medeiros, Hetty E. Carraway, Olga Frankfurt, Stephen J. Forman, Xuezhong A. Yang, Marina Konopleva, Francine Garnache-Ottou, Fanny Angelot-Delettre, Christopher Brooks, Michael Szarek, Eric Rowinsky

Blood (2014) 124 (3): 385–392.

https://doi.org/10.1182/blood-2014-04-566737

Published: 2014

Journal Articles

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Arthur E. Frankel, MD, Jung H. Woo, PhD, Jeremy P. Mauldin, PhD, Hetty E. Carraway, MD, MBA, Olga Frankfurt, MD, Stephen J. Forman, MD, Sumithira Vasu, MBBS, Naveen Pemmaraju, MD, Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, Francine Garanache-Ottou, Ph.D., Fanny Angelot-Delettre, PhD, Christopher Brooks, PhD, Michael Szarek, PhD, Ivan Bergstein, MD, Eric Rowinsky, MD

Blood (2013) 122 (21): 2682.

https://doi.org/10.1182/blood.V122.21.2682.2682

Published: 2013

Journal Articles

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, David A. Rizzieri, MD, Thomas P. Cirrito, PhD, Steven M. Kornblau, MD, PhD, Gautam Borthakur, M.D., Carol Bivins, RN, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Farhad Ravandi, MD, Michael Andreeff, MD, PhD, Jorge E. Cortes, MD, Kenneth Hoberman, Michael Szarek, PhD, Eric Rowinsky, MD, Ivan Bergstein, MD, Hagop M. Kantarjian, MD, Arthur E. Frankel, MD

Blood (2012) 120 (21): 3625.

https://doi.org/10.1182/blood.V120.21.3625.3625

Published: 2012

NARROW

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Email alerts

ASH Publications

American Society of Hematology

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only